ImmunityBio Acquires U.S. Rights to Tokyo Strain of BCG

ImmunityBio has announced its acquisition of the U.S. rights to the Tokyo strain of Bacillus Calmette-Guérin (BCG), a vaccine primarily used against tuberculosis and also for bladder cancer treatment.